Table 1.

Patient characteristics a

VariableGroupPb
Placebo(n = 20)ND(n = 19)EX(n = 20)ND+EX(n = 20)
Age (yr)56.8 ± 13.855.7 ± 13.454.4 ± 13.655.5 ± 12.50.95
Gender, male/female14/610/912/813/70.72
Comorbidities (n [%])
    diabetes8 (40)10 (53)12 (60)9 (45)0.61
    hypertension17 (85)18 (95)18 (90)20 (100)0.32
    coronary artery disease7 (35)7 (37)7 (35)9 (45)0.90
    peripheral arterial disease4 (20)2 (11)2 (10)2 (10)0.73
    cerebrovascular disease3 (15)04 (20)1 (5)0.15
BMI (kg/m2)27.8 ± 6.524.8 ± 4.627.4 ± 5.327.8 ± 9.70.45
Kt/V1.4 ± 0.31.4 ± 0.21.4 ± 0.31.3 ± 0.30.69
Dialysis vintage (mo)c25.5 (3, 156)40.0 (3, 288)33.0 (3.5, 108)14.0 (4, 152)0.23
Hemoglobin (g/dl)11.5 ± 1.611.7 ± 1.611.9 ± 0.912.4 ± 1.70.29
Albumin (g/dl)3.8 ± 0.43.9 ± 0.44.0 ± 0.54.0 ± 0.40.61
Predialysis BUN (mg/dl)61 ± 1661 ± 1758 ± 1662 ± 150.87
Predialysis serum creatinine (mg/d)11.0 ± 3.410.2 ± 2.410.0 ± 3.29.7 ± 2.70.59
  • a Data are mean ± SD, except as noted otherwise. BMI, body mass index; BUN, blood urea nitrogen concentration; EX, lower extremity resistance exercise training; ND, nandrolone decanoate; ND+EX, nandrolone decanoate plus resistance exercise training.

  • b ANOVA for continuous variables; Kruskal Wallis for dichotomous and nonnormal variables.

  • c Results reported as median (minimum, maximum) because of nonnormal distribution.\